Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients
Authors
Keywords
Non-small cell lung cancer, Programmed death-ligand 1, Immunohistochemistry, Clinical pathology, Interlaboratory variation
Journal
LUNG CANCER
Volume 159, Issue -, Pages 117-126
Publisher
Elsevier BV
Online
2021-07-23
DOI
10.1016/j.lungcan.2021.07.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
- (2020) Cleo Keppens et al. VIRCHOWS ARCHIV
- PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory
- (2019) Elena Vigliar et al. JOURNAL OF CLINICAL PATHOLOGY
- Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
- (2019) Carmen van Dooijeweert et al. BREAST CANCER RESEARCH AND TREATMENT
- CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki‐67 clone 30‐9 is not susceptible to the inhibition: Critical diagnostic implications
- (2019) Darren J. Buonocore et al. CANCER CYTOPATHOLOGY
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
- (2019) Emina Torlakovic et al. MODERN PATHOLOGY
- The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
- (2019) Birgit Guldhammer Skov et al. MODERN PATHOLOGY
- P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative
- (2019) J. Adam et al. Journal of Thoracic Oncology
- Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
- (2019) Erik Thunnissen et al. MODERN PATHOLOGY
- Comparability of PD‐L1 immunohistochemistry assays for non‐small cell lung cancer: a systematic review
- (2019) Bregje M. Koomen et al. HISTOPATHOLOGY
- Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer
- (2019) Rogier Butter et al. JOURNAL OF CLINICAL PATHOLOGY
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas
- (2018) Eleanor Russell-Goldman et al. CANCER CYTOPATHOLOGY
- Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients
- (2018) Marius Ilie et al. CANCER CYTOPATHOLOGY
- Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis
- (2018) Fausto Petrelli et al. Clinical Lung Cancer
- Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma
- (2018) Viktor H Koelzer et al. HISTOPATHOLOGY
- Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients
- (2018) Lívia Rojkó et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma
- (2018) Anthony W. H. Chan et al. MODERN PATHOLOGY
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Cell blocks in cytopathology: An update
- (2018) Aruna Nambirajan et al. CYTOPATHOLOGY
- Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
- (2018) Y -L Wu et al. ANNALS OF ONCOLOGY
- How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non–Small Cell Lung Cancer
- (2018) Erik Thunnissen ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands
- (2018) Carmen van Dooijeweert et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer
- (2018) Peng Song et al. JOURNAL OF IMMUNOTHERAPY
- Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features
- (2018) Linda Ye et al. MODERN PATHOLOGY
- Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
- (2018) Vamsidhar Velcheti et al. PLoS One
- Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
- (2017) Andreas H Scheel et al. HISTOPATHOLOGY
- Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
- (2017) Antonio Marchetti et al. Journal of Thoracic Oncology
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods
- (2017) Isaac E. Lloyd et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
- (2017) Birgit G. Skov et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Interlaboratory Variability in the Histologic Grading of Colorectal Adenocarcinomas in a Nationwide Cohort
- (2016) Chantal C.H.J. Kuijpers et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
- (2016) Keith M. Kerr et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Young investigator challenge: Validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens
- (2016) Jennifer L. Sauter et al. CANCER CYTOPATHOLOGY
- Interlaboratory variability in the grading of dysplasia in a nationwide cohort of colorectal adenomas
- (2016) Chantal C H J Kuijpers et al. HISTOPATHOLOGY
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
- (2016) Charlotte Roach et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- CytoLyt® Fixation and Decalcification Pretreatments Alter Antigenicity in Normal Tissues Compared With Standard Formalin Fixation
- (2015) Jennette R. Gruchy et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Comparison of Breast Carcinoma Prognostic/Predictive Biomarkers on Cell Blocks Obtained by Various Methods: Cellient, Formalin and Thrombin
- (2012) Blythe K. Gorman et al. ACTA CYTOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now